dismissed by the arbitration court. The ruling confirmed that Santaris held exclusive worldwide rights to manufacture, have manufactured, and sell products that comprise LNA as active ingredient for studies performed with a purpose of developing LNA-based drugs for marketing approval. Santaris Pharama A/S vs. Isis Pharmaceuticals Isis Pharmaceuticals filed a patent infringement lawsuit against Santaris Pharma A/S in the United States District Court of the Southern District of California in September 2011. Isis's infringement suit against Santaris is based upon Santaris's activities providing antisense drugs and antisense drug discovery services to several pharmaceutical companies. References Pharmaceutical companies of Denmark Pharmaceutical companies established in 2003